ROCKET PHARMACEUTICALS, INC. — Form 8-K
Filed October 6, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 71/100
What the filing says
Rocket Pharmaceuticals entered into a Loan and Security Agreement dated September 30, 2026, with Hercules Capital, Inc. as agent and lender, for up to $150,000,000 in aggregate Term Loan Advances across five tranches. The facility is secured by substantially all company assets and is structured to support development of RP-A501 for Danon Disease, with tranche availability contingent on regulatory milestones including an FDA approval milestone for a Biologics License Application.
Why this rating
At $150M against $212.5M market cap, this represents ~71% of company value—transformational liquidity for a clinical-stage biotech. Materially extends runway and de-risks near-term operations, but carries substantial obligations and restrictive covenants.
Price action (we called it positive)
before filing · preread $2.51 | at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from October 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.